Therapeutic and technological advancements in haemophilia care: Quantum leaps forward. (6th May 2022)

• Record Type: Journal Article
• Authors: Lewandowska, Magdalena; Nasr, Sonia; Shapiro, Amy D.
• Other Names: James Paula guestEditor.; Pipe Steven guestEditor.; Srivastava Alok guestEditor.
• Is Part Of: Haemophilia. Volume 28(2022)Supplement 4
• Page Start: 77
• Page End: 92
• Publication Date: 2022-05-06
• Subjects: gene therapy, health equity, haemophilia -- mimetics -- MSKUS -- novel therapies -- technology; Hemophilia -- Periodicals; 616.1572005
• DOI: 10.1111/hae.14531
• Languages: English
• ISSNs: 1351-8216

Abstract

Abstract: Introduction: Recent technological innovations in haemophilia have advanced at an astounding pace, including gene therapy programmes and bioengineered molecules for prophylaxis, products that reduce treatment burden through half‐life extension, unique mechanisms of action, and subcutaneous administration. Additional technological advancements have emerged that are anticipated to further transform haemophilia care. Aim: Review new and emerging haemophilia therapies, including replacement and bypassing products, digital applications, utilisation of big data, and personalised medicine. Methods: Data were obtained from peer‐reviewed presentations/publications, and ongoing studies in haemophilia, ultrasonography, and artificial intelligence (AI). Results: Available treatments include new recombinant factors VIII (FVIII) and IX (FIX), extended half‐life FVIII/IX products, a new FVIIa product for inhibitor patients, and a FVIIIa‐mimetic. Several novel therapeutics are in clinical trials, including FVIIIa mimetics and inhibitors of naturally‐occurring anticoagulants. Ongoing gene therapy trials suggest that a single vector infusion using an optimised construct can produce factor activity that reduces bleeding to near zero for years. Today, persons with haemophilia (PwH) approach a lifespan comparable to that of the general population, presenting treatment challenges for age‐related co‐morbidities. Technological innovations have broadened beyond therapeutics to include large database analyses utilising remote data collection with handheld devices, and to tailor AI applications. Current development efforts include patient‐performed ultrasonography, algorithms for scan interpretation, and point‐of‐care haemostatic testing devices. Conclusions: We have entered a golden age for haemophilia treatment and care with wide‐ranging advancements targeting improved quality of life (QoL). Future‐focused efforts by clinical and patient communities may provide equitable access and care for people impacted by haemophilia worldwide. Abstract :